EICHOR
● Active Not Recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Condition: Endometrial Cancer · Sponsor: Karyopharm Therapeutics Inc
About this study
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (204)
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Honor Health | Phoenix, Arizona, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| UC DAVIS | Davis, California, United States | — |
| City of Hope National Medical Center | Duarte, California, United States | — |
| City of Hope at Irvine Lennar | Irvine, California, United States | — |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | — |
| UCLA - Women's Health Clinical Research Unit | Los Angeles, California, United States | — |
| Long Beach Memorial Medical Center | Los Angeles, California, United States | — |
| Stanford University | Palo Alto, California, United States | — |
| California Pacific Medical Center | San Francisco, California, United States | — |
| Broward Health Medical Center | Fort Lauderdale, Florida, United States | — |
+ 192 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05611931